List view / Grid view
26 February 2016 | By Sini Eskola, Director, European Federation of Pharmaceutical Industries and Associations (EFPIA)
This review looks at the steps needed to complete clinical trials in the European Union (EU) and describes the rigorous regulatory framework involved in clinical research...
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
15 February 2016 | By Robert Yardy, Head of New Business and Marketing, MMT Digital
Robert Yardy of MMT Digital, a company that redeveloped Allergan's corporate website, discusses the value to pharmaceutical companies of having a responsive, fully functional website...
10 February 2016 | By Victoria White, European Pharmaceutical Review
The MRC has launched a £1m rapid response funding initiative to better understand the nature of the risk posed by the Zika virus. Find out about this initiative and NIH's call for research here...
4 February 2016 | By Victoria White, European Pharmaceutical Review
The Zika virus has taken hold in South America. Its possible link to microcephaly in newborn babies and neurological conditions has led the World Health Organization to declare a Public Health Emergency of International Concern. Here we discuss the virus, countermeasures and the race for a vaccine.
29 January 2016 | By Adewale Joseph Ogunleye, Adekunle Ajasin University, Akungba Akoko, Ondo State, Nigeria
This article explores how scientists are developing a fast, qualitative and specific technique for the detection and classification of microorganisms...
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
19 January 2016 | By Snehal Chougule, Allied Market Research
Snehal Chougule discusses the ovarian cancer treatment market and recent approvals by the US Food and Drug Administration...
In digital version of Issue #6 2015: Microbiology, Screening, PCR, Continuous Manufacturing, PAT, Regulation, and much more...
Our Application Notes & Whitepapers supplement covers a wide variety of applications, from NMR, biosensors, Raman spectroscopy and QC to hot-stage microscopy...
6 January 2016 | By Caroline Richards
In this Screening In-depth Focus: High-content screening accelerates discovery rates in the life sciences; Phenotypic screening using 3D tissue culture and whole animal assays; Screening Roundtable...
Featuring an overview of process analytical control; Beyond API monitoring: in-line Raman spectroscopy for process control; Monitoring, understanding and assessing pharmaceutical process and product quality; and a PAT roundtable...
6 January 2016 | By Dave Elder, GlaxoSmithKline and JPAG
The International Conference on Harmonization M7 text provides guidance on establishing acceptable levels of mutagenic impurities (MIs) . It also outlines the safety and quality risk management processes that manufacturers need to undertake to control MIs that may potentially affect the drug substance or drug product. Over the past decade,…
6 January 2016 | By Tony Cundell, Microbiological Consulting LLC
The recent revision to USP General Informational Chapter Validation of Alternative Microbiological Methods that became official on December 1, 2015 contained a section discussing the limitations of the colony-forming unit (CFU) in terms of enumerating only those microorganisms that readily grow on solid microbiological media. The section highlights its inappropriateness…
6 January 2016 | By Irmgard Riedmaier, Melanie Spornraft, Benedikt Kirchner and Michael W. Pfaffl, Technical University of Munich
Molecular diagnostics and biomarker discovery are gaining increasing attraction in clinical research. This includes all fields of diagnostics, such as risk assessment, disease prognosis, treatment prediction and drug application success control. The detection of molecular clinical biomarkers is very widespread and can be developed on various molecular levels, like the…
